Hair Loss & Scalp Health

Dutasteride / Minoxidil / Biotin / Vitamin D3 / Vitamin K2

A multi-ingredient compounded option for androgen-related hair-loss and scalp-support programs.

Evidence brief in review

lennoxHAIRProduct image pending

Common goals: Potential support for androgenetic-alopecia goals through DHT reduction and minoxidil activity.
Best program fit: May fit a clinician-connected hair program after the cause of hair loss, route, ingredient strengths, and reproductive considerations are reviewed.
Format: Compounded combination · exact dosage form to be confirmed

Partner education guide

Where this may fit in an offering.

Potential support for androgenetic-alopecia goals through DHT reduction and minoxidil activity. One formula may simplify a multi-ingredient routine. May fit a clinician-connected hair-loss program with long-term tracking.

Educational business-planning summary. Potential benefits vary, are not guaranteed, and require individual-specific clinical review.

01 / Common goals

What people may want to understand.

Primary goals

Potential benefits and goals

Potential support for androgenetic-alopecia goals through DHT reduction and minoxidil activity.
One formula may simplify a multi-ingredient routine.
Photography and scalp assessment can support measurable follow-up.

Program value

How it may support a program

May fit a clinician-connected hair-loss program with long-term tracking.
Nutrient review can identify whether added micronutrients address a documented need.

Dutasteride has off-label alopecia evidence and minoxidil evidence is route-specific. The exact compounded combination, route, strengths, and nutrient contribution are not established.

02 / Program fit

Program and operational considerations.

01Administration format: Catalog format: Compounded combination · exact dosage form to be confirmed. The prescribing clinician and dispensing pharmacy confirm the exact preparation, concentration, handling, and administration technique.
02Typical frequency: The screenshot does not establish a schedule. Frequency must come from the exact prescription and route-specific product instructions.
03Expected duration: Hair-loss treatment is usually assessed over months and often requires continued use to maintain benefit. The exact combination has no product-matched duration study.
04Practical considerations: May fit a clinician-connected hair-loss program with long-term tracking.

03 / Suitability considerations

Who may be considered.

Who may be considered

A carefully screened adult whose goals align with the potential benefits above and who understands that individual response varies.
An individual willing to complete clinician-directed baseline review, monitoring, and an outcome-based follow-up plan.

Qualification notes

May fit a clinician-connected hair-loss program with long-term tracking.
Strongest fit occurs when the exact formulation, route, source, contraindications, and measurable goals can be clearly documented.

04 / Safety & suitability

What must be screened before treatment.

Common or temporary

Sexual adverse effects can include reduced libido, erectile or ejaculation changes, and reduced semen volume; breast tenderness or enlargement may occur.
Minoxidil effects depend on route. Topical use may cause scalp irritation, itching, unwanted facial hair, or temporary shedding; systemic exposure can cause dizziness, swelling, or a faster heartbeat.

Serious or important

Finasteride or dutasteride can affect pregnancy through exposure to the active drug and can change prostate-specific antigen interpretation. Reproductive plans and handling precautions require review.
Chest pain, fainting, rapid heartbeat, sudden swelling, serious mood change, allergic reaction, or a painful scalp reaction warrants prompt assessment.

Avoid or use only with specialist input

Pregnancy or potential pregnancy where exposure to finasteride or dutasteride could occur, hypersensitivity to a formula ingredient, or an unverified compounded product.
Sudden, patchy, scarring, inflamed, infected, or unexplained hair loss until an appropriate diagnosis is established.

Screening checklist

Confirm the hair-loss pattern and duration, scalp findings, family history, current medicines and supplements, blood-pressure and heart history, reproductive plans, sexual symptoms, mood history, and relevant laboratory evaluation.
Verify the exact dosage form, route, ingredient strengths, dispensing pharmacy, storage, and how progress will be photographed or measured.

When to refer

Refer for dermatology or medical assessment when hair loss is sudden, patchy, scarring, associated with inflammation or systemic symptoms, occurs in a child, or remains diagnostically unclear.
Prompt assessment is appropriate for chest pain, syncope, marked edema, a persistent rapid heartbeat, severe scalp reaction, pregnancy exposure, or significant sexual or mood symptoms.

Safety information is not exhaustive. Prescribing, screening, dosing, monitoring, and emergency guidance must come from an appropriately licensed clinician and the exact product information.

What the research says · reviewed August 2026

Research and source context.

Dutasteride and minoxidil have ingredient-level hair-loss evidence, but the route, strengths, and added nutrients determine whether that evidence applies.

01 / Human research

The clearest clinical signal

Randomized studies support dutasteride activity in male androgenetic alopecia, and topical minoxidil has labeled hair-regrowth evidence. The full combination has not been tested as one product.

02 / Real-world reports

What people describe

People may value one coordinated hair-loss formula, but they should understand the off-label status, reproductive precautions, sexual adverse effects, and need for months of follow-up.

Public personal accounts are unverified and cannot show how common an outcome is.

03 / Cautions

What deserves attention

Route-specific minoxidil cardiovascular effects, dutasteride reproductive and sexual risks, prostate-marker interpretation, and compounded-product quality require review.

Does the research match this exact product?

No. The evidence supports selected ingredients and routes, not this exact compounded combination.

Research and regulatory context

Randomized studies support dutasteride activity in male androgenetic alopecia, while approved minoxidil labeling supports specific topical formats. No controlled trial establishes this exact five-ingredient compounded product, route, or nutrient contribution.

Complete evidence briefClinical summary, safety notes, reported timing, regulatory context, and linked sources in one document.

Evidence brief in reviewReviewed sources are listed above

Evidence and regulatory status can change. Confirm the current label, formulation, route, dose, pharmacy source, jurisdiction, and intended use before offering treatment.

Education before offering.

Treatment information is for education only. It is not medical advice. A licensed clinician will review your health and decide whether a treatment is appropriate for you. Eligibility and availability may vary.

Back to all treatments